Payment overview · 2025
General Payments
$45.69
2 reported records · 2 companies
Healthcare provider profile · identity verified
Karah A Parker
Allopathic & Osteopathic Physicians|Family Medicine · LAKELAND, FL · NPI 1346801545
Verified facts
What the public records show
CMS Open Payments records show Karah A Parker received $45.69 in general payments during 2025 across 2 reported records.
Dexcom, Inc. accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Armour Thyroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.44 | 53.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.25 | 46.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.69 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 128 |
| Lisinopril | Lisinopril | 367 | 122 |
| Losartan Potassium | Losartan Potassium | 349 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 103 |
| Tizanidine Hcl | Tizanidine Hcl | 270 | 107 |
| Gabapentin | Gabapentin | 255 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 83 |
| Omeprazole | Omeprazole | 225 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 221 | 61 |
| Metformin Hcl | Metformin Hcl | 216 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 33 |
| Furosemide | Furosemide | 148 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 50 |
| Tramadol Hcl | Tramadol Hcl | 141 | 35 |
| Trazodone Hcl | Trazodone Hcl | 136 | 56 |
| Finasteride | Finasteride | 125 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 122 | 40 |
| Alprazolam | Alprazolam | 119 | 29 |
| Buspirone Hcl | Buspirone Hcl | 118 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 37 |
| Methylprednisolone | Methylprednisolone | 103 | 82 |
| Montelukast Sodium | Montelukast Sodium | 103 | 38 |
| Warfarin Sodium | Warfarin Sodium | 99 | 24 |
| Carvedilol | Carvedilol | 93 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 34 |
| Meloxicam | Meloxicam | 85 | 27 |
| Metformin Hcl Er | Metformin Hcl | 84 | 20 |
| Sertraline Hcl | Sertraline Hcl | 84 | 33 |
| Azithromycin | Azithromycin | 83 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 31 |
| Temazepam | Temazepam | 79 | suppressed |
| Glipizide | Glipizide | 77 | 26 |
| Potassium Chloride | Potassium Chloride | 77 | 28 |
| Prednisone | Prednisone | 77 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 32 |
| Allopurinol | Allopurinol | 70 | 24 |
| Clonazepam | Clonazepam | 70 | 14 |
| Fenofibrate | Fenofibrate | 65 | 24 |
| Spironolactone | Spironolactone | 63 | 15 |
| Eliquis | Apixaban | 62 | 18 |
| Glimepiride | Glimepiride | 58 | 14 |
| Atenolol | Atenolol | 53 | 17 |
| Ezetimibe | Ezetimibe | 52 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Simvastatin | Simvastatin | 50 | 20 |
| Bumetanide | Bumetanide | 49 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Nystatin | Nystatin | 49 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 18 |
| Alendronate Sodium | Alendronate Sodium | 45 | 19 |
| Mupirocin | Mupirocin | 45 | 38 |
| Bupropion Hcl | Bupropion Hcl | 43 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 19 |
| Pregabalin | Pregabalin | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | 20 |
| Bupropion Xl | Bupropion Hcl | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Famotidine | Famotidine | 36 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 18 |
| Glipizide Er | Glipizide | 35 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 26 |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | 13 |
| Progesterone | Progesterone, Micronized | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 17 |
| Valsartan | Valsartan | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Fluconazole | Fluconazole | 17 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dupixent Syringe | Dupilumab | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.69 · 2 records | Dexcom, Inc. | CREON, Dexcom G6 Transmitter, LINZESS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error